• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
SUN Shoufei,ZHANG Jing,XUE Xiaoxia,ZHAO Jie.Clinical research progress of novel antiviral RNA polymerase PA subunit inhibitor[J].Journal Of Pharmaceutical Research,2024,43(1):89-92[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2959times   Download 2361次 QR Code for this article
Scan with your phone!
新型抗病毒RNA聚合酶PA亚基抑制剂临床研究进展
孙守飞1,张静2,薛晓霞2,赵杰3
Font:Larger+|Default|Smaller-
(1.山东辰欣佛都药业股份有限公司,山东 济宁 272500;2.辰欣药业股份有限公司,山东 济宁 272073;3.山东省食品药品审评查验中心,山东 济南 250014)
摘要:
流行性感冒(简称流感)是流感病毒引起的对人类健康危害较重的呼吸道传染病。目前抗流感药物的应用主要面临病毒耐药性和对高致病性流感病毒的效价低的问题,如M2离子通道抑制剂和神经氨酸酶抑制剂存在药效低、时间窗口窄和耐药性等缺点。近来的抗流感药物研发的靶点聚焦于病毒RNA聚合酶。流感病毒RNA聚合酶是病毒在宿主细胞内完成复制和转录过程的关键酶,其中PA亚基通过内切酶活性为流感病毒的转录过程提供引物,成为潜在抗流感药物靶点。本文总结了以PA亚基内切酶为靶点的抗流感药物研究进展,旨在为开发安全有效的新型抗病毒RNA聚合酶抑制剂提供参考。
关键词:  流感病毒  病毒RNA聚合酶  PA亚基  临床药效  安全性  不良反应
DOI:10.13506/j.cnki.jpr.2024.01.016
基金项目:济宁市重点研发计划(产业创新重大技术“全球揭榜”)项目(No.2022JBZP005)
Publication Date:January 25, 2024
Clinical research progress of novel antiviral RNA polymerase PA subunit inhibitor
SUN Shoufei1,ZHANG Jing2,XUE Xiaoxia2,ZHAO Jie3
(1. Shandong Cisen Fodu Pharmaceutical Co., Ltd., Jining 272500,China;2. Cisen Pharmaceutical Co., Ltd., Jining 272073,China;3.Shandong Engineering Laboratory for Standard Innovation and Quality Evaluation of TCM, Jinan 250101,China)
Abstract:
Influenza is a respiratory infectious disease caused by influenza virus, which is more harmful to human health. At present, the main problems faced by anti influenza drugs are virus resistance and low potency for highly pathogenic influenza virus. Due to the shortcomings of influenza drugs such as M2 Ion channel inhibitor and Neuraminidase inhibitor, such as low efficacy, narrow time window and drug resistance, recent anti influenza Drug development focuses on viral RNA polymerase. Influenza virus RNA polymerase is a key enzyme for virus replication and transcription in host cells. The PA subunit provides primers for the transcription process of influenza virus through Endonuclease activity and becomes a potential anti influenza drug target. Therefore, this article summarized the research progress of anti influenza drugs targeting the activity of PA subunit Endonuclease, aiming to provide a reference for the development of new safe and effective antiviral RNA polymerase inhibitors.
Key words:  Influenza virusꎻVirus RNA polymeraseꎻPA SubunitꎻClinical efficacyꎻSafetyꎻAdverse reaction
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.